Details of the Drug

General Information of Drug (ID: DMAOL2S)

Drug Name
Voriconazole
Synonyms
VCZ; Vfend; Pfizer brand of voriconazole; UK 109496; Voriconazole in combination with MGCD290; DRG-0301; UK 109,496; UK-109496; VFEND (TN); Vfend (TN); Vfend, Voriconazole; UK-109,496; Voriconazole [USAN:INN:BAN]; Voriconazole (JAN/USAN/INN); (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; (R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; (alphaR,betaS)-alpha-(2,4-Difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; (alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; VRC
Indication
Disease Entry ICD 11 Status REF
Invasive aspergillosis 1F20.0 Approved [1]
Therapeutic Class
Antifungal Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 349.31
Topological Polar Surface Area (xlogp) 1.5
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1-2 h [2]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability
The bioavailability of drug is 96% [2]
Clearance
The clearance of drug is 5.25-7 L/h in healthy adults [4]
Elimination
Voriconazole is eliminated via hepatic metabolism with less than 2% of the dose excreted unchanged in the urine [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 5.6 hours [5]
Metabolism
The drug is metabolized via the hepatic [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 34.35442 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.42% [5]
Vd
The volume of distribution (Vd) of drug is 4.6 L/kg [2]
Water Solubility
The ability of drug to dissolve in water is measured as 0.39 mg/mL [3]
Chemical Identifiers
Formula
C16H14F3N5O
IUPAC Name
(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol
Canonical SMILES
C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O
InChI
InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1
InChIKey
BCEHBSKCWLPMDN-MGPLVRAMSA-N
Cross-matching ID
PubChem CID
71616
ChEBI ID
CHEBI:10023
CAS Number
188416-29-7
DrugBank ID
DB00582
TTD ID
D0N3VR
VARIDT ID
DR00445
INTEDE ID
DR1709
ACDINA ID
D00733

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Candida Cytochrome P450 51 (Candi ERG11) TTTSOUD CP51_CANAL Modulator [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [9]
Cytochrome P450 2C9 (CYP2C9)
Main DME 		DE5IED8 CP2C9_HUMAN Substrate [10]
Mephenytoin 4-hydroxylase (CYP2C19)
Main DME 		DEGTFWK CP2CJ_HUMAN Substrate [10]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Substrate [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Voriconazole
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Posaconazole. Aspergillosis [1F20] [44]
Coadministration of a Drug Treating the Disease Different from Voriconazole (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Voriconazole and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [45]
Clindamycin DM15HL8 Moderate Decreased metabolism of Voriconazole caused by Clindamycin mediated inhibition of CYP450 enzyme. Acne vulgaris [ED80] [46]
Tretinoin DM49DUI Major Decreased metabolism of Voriconazole caused by Tretinoin mediated inhibition of CYP450 enzyme. Acne vulgaris [ED80] [47]
Repaglinide DM5SXUV Moderate Decreased metabolism of Voriconazole caused by Repaglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [48]
Glibenclamide DM8JXPZ Major Decreased metabolism of Voriconazole caused by Glibenclamide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [49]
Tolazamide DMIHRNA Major Decreased metabolism of Voriconazole caused by Tolazamide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [49]
Pioglitazone DMKJ485 Moderate Decreased metabolism of Voriconazole caused by Pioglitazone mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [45]
Nateglinide DMLK2QH Moderate Decreased metabolism of Voriconazole caused by Nateglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [50]
Glipizide DMZA5PQ Major Decreased metabolism of Voriconazole caused by Glipizide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [49]
Ivosidenib DM8S6T7 Major Decreased metabolism of Voriconazole caused by Ivosidenib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [51]
Midostaurin DMI6E0R Major Decreased metabolism of Voriconazole caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [52]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Idarubicin. Acute myeloid leukaemia [2A60] [44]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Daunorubicin. Acute myeloid leukaemia [2A60] [53]
Arn-509 DMT81LZ Moderate Increased metabolism of Voriconazole caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [54]
Oliceridine DM6MDCF Major Decreased metabolism of Voriconazole caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [55]
Mitotane DMU1GX0 Moderate Increased metabolism of Voriconazole caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [54]
Galantamine DMEO794 Moderate Decreased metabolism of Voriconazole caused by Galantamine mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [56]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Voriconazole and Rivastigmine. Alzheimer disease [8A20] [44]
Donepezil DMIYG7Z Minor Decreased metabolism of Voriconazole caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [57]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Voriconazole and Metronidazole. Amoebiasis [1A36] [45]
Ivabradine DM0L594 Major Decreased metabolism of Voriconazole caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [45]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Voriconazole and Bepridil. Angina pectoris [BA40] [44]
Dronedarone DMA8FS5 Major Decreased metabolism of Voriconazole caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [45]
Nifedipine DMSVOZT Moderate Decreased metabolism of Voriconazole caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [58]
Bedaquiline DM3906J Major Decreased metabolism of Voriconazole caused by Bedaquiline mediated inhibition of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [59]
Clorazepate DMC3JST Moderate Decreased metabolism of Voriconazole caused by Clorazepate mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [45]
Methylphenobarbital DMDSWAG Major Increased metabolism of Voriconazole caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [44]
Cilostazol DMZMSCT Major Decreased metabolism of Voriconazole caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [50]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Levalbuterol. Asthma [CA23] [60]
Terbutaline DMD4381 Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Terbutaline. Asthma [CA23] [61]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Voriconazole and Pirbuterol. Asthma [CA23] [61]
Budesonide DMJIBAW Major Decreased metabolism of Voriconazole caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [62]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Salbutamol. Asthma [CA23] [60]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Voriconazole and Formoterol. Asthma [CA23] [61]
Zileuton DMVRIC2 Moderate Decreased metabolism of Voriconazole caused by Zileuton mediated inhibition of CYP450 enzyme. Asthma [CA23] [45]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [50]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Desipramine. Attention deficit hyperactivity disorder [6A05] [44]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Ofloxacin. Bacterial infection [1A00-1C4Z] [63]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Clarithromycin. Bacterial infection [1A00-1C4Z] [44]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Voriconazole and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [44]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Voriconazole and Sparfloxacin. Bacterial infection [1A00-1C4Z] [63]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Gemifloxacin. Bacterial infection [1A00-1C4Z] [63]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Norfloxacin. Bacterial infection [1A00-1C4Z] [63]
Rabeprazole DMMZXIW Moderate Decreased metabolism of Voriconazole caused by Rabeprazole mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [64]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Voriconazole caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [45]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Lomefloxacin. Bacterial infection [1A00-1C4Z] [44]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Retigabine. Behcet disease [4A62] [44]
Cariprazine DMJYDVK Major Decreased metabolism of Voriconazole caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [65]
Erdafitinib DMI782S Major Decreased metabolism of Voriconazole caused by Erdafitinib mediated inhibition of CYP450 enzyme. Bladder cancer [2C94] [66]
Pexidartinib DMS2J0Z Major Decreased metabolism of Voriconazole caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [67]
Loperamide DMOJZQ9 Major Decreased metabolism of Voriconazole caused by Loperamide mediated inhibition of CYP450 enzyme. Bowel habit change [ME05] [68]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Eribulin. Breast cancer [2C60-2C6Y] [44]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Voriconazole caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [69]
Lapatinib DM3BH1Y Major Decreased metabolism of Voriconazole caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [45]
HKI-272 DM6QOVN Major Decreased metabolism of Voriconazole caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [70]
LY2835219 DM93VBZ Major Decreased metabolism of Voriconazole caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [71]
Esterified estrogens DM9KZDO Moderate Decreased metabolism of Voriconazole caused by Esterified estrogens mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [72]
Tucatinib DMBESUA Moderate Decreased metabolism of Voriconazole caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [73]
Palbociclib DMD7L94 Major Decreased metabolism of Voriconazole caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [74]
Alpelisib DMEXMYK Moderate Increased metabolism of Voriconazole caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [75]
Quinestrol DMJ6H1Z Moderate Decreased metabolism of Voriconazole caused by Quinestrol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [72]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Tamoxifen. Breast cancer [2C60-2C6Y] [44]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Voriconazole caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [45]
Bosutinib DMTI8YE Major Decreased metabolism of Voriconazole caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [45]
Trastuzumab Emtansine DMU1LXS Moderate Decreased metabolism of Voriconazole caused by Trastuzumab Emtansine mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [45]
Estradiol DMUNTE3 Moderate Decreased metabolism of Voriconazole caused by Estradiol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [72]
Atorvastatin DMF28YC Major Decreased metabolism of Voriconazole caused by Atorvastatin mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [76]
Macitentan DMP79A1 Major Decreased metabolism of Voriconazole caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [77]
PF-04449913 DMSB068 Major Decreased metabolism of Voriconazole caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [78]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Voriconazole and Olodaterol. Chronic obstructive pulmonary disease [CA22] [61]
Salmeterol DMIEU69 Major Decreased metabolism of Voriconazole caused by Salmeterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [45]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Indacaterol. Chronic obstructive pulmonary disease [CA22] [61]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Voriconazole and Arformoterol. Chronic obstructive pulmonary disease [CA22] [61]
Levomilnacipran DMV26S8 Major Decreased metabolism of Voriconazole caused by Levomilnacipran mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [79]
Anisindione DM2C48U Major Decreased metabolism of Voriconazole caused by Anisindione mediated inhibition of CYP450 enzyme. Coagulation defect [3B10] [54]
Regorafenib DMHSY1I Moderate Decreased metabolism of Voriconazole caused by Regorafenib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [45]
Irinotecan DMP6SC2 Major Decreased metabolism of Voriconazole caused by Irinotecan mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [44]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Voriconazole and Isoproterenol. Conduction disorder [BC63] [60]
Drospirenone DM1A9W3 Major Decreased metabolism of Voriconazole caused by Drospirenone mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [45]
Levonorgestrel DM1DP7T Moderate Decreased metabolism of Voriconazole caused by Levonorgestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [72]
Ulipristal DMBNI20 Minor Decreased metabolism of Voriconazole caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [50]
Levobupivacaine DM783CH Moderate Decreased metabolism of Voriconazole caused by Levobupivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [50]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Halothane. Corneal disease [9A76-9A78] [44]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Sevoflurane. Corneal disease [9A76-9A78] [44]
Cocaine DMSOX7I Moderate Decreased metabolism of Voriconazole caused by Cocaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [45]
Alfentanil DMVO0UB Major Decreased metabolism of Voriconazole caused by Alfentanil mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [80]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Probucol. Coronary atherosclerosis [BA80] [44]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Clofazimine. Crohn disease [DD70] [81]
Mifepristone DMGZQEF Major Decreased metabolism of Voriconazole caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [82]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Voriconazole and Pasireotide. Cushing syndrome [5A70] [44]
Osilodrostat DMIJC9X Major Decreased metabolism of Voriconazole caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [50]
Ivacaftor DMZC1HS Major Decreased metabolism of Voriconazole caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [45]
MK-8228 DMOB58Q Moderate Increased metabolism of Voriconazole caused by MK-8228 mediated induction of CYP450 enzyme. Cytomegaloviral disease [1D82] [83]
Rivaroxaban DMQMBZ1 Major Decreased clearance of Voriconazole due to the transporter inhibition by Rivaroxaban. Deep vein thrombosis [BD71] [45]
Aprepitant DM053KT Moderate Decreased metabolism of Voriconazole caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [84]
Trimipramine DM1SC8M Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Trimipramine. Depression [6A70-6A7Z] [44]
Cyclobenzaprine DM1YBRM Moderate Decreased metabolism of Voriconazole caused by Cyclobenzaprine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [45]
Vilazodone DM4LECQ Major Decreased metabolism of Voriconazole caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [85]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Voriconazole caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [45]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Voriconazole and Escitalopram. Depression [6A70-6A7Z] [44]
OPC-34712 DMHG57U Major Decreased metabolism of Voriconazole caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [86]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Clomipramine. Depression [6A70-6A7Z] [44]
Trazodone DMK1GBJ Moderate Decreased metabolism of Voriconazole caused by Trazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [87]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Doxepin. Depression [6A70-6A7Z] [44]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Maprotiline. Depression [6A70-6A7Z] [44]
Polatuzumab vedotin DMF6Y0L Major Decreased metabolism of Voriconazole caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [88]
[3H]estrone-3-sulphate DMGPF0N Moderate Decreased metabolism of Voriconazole caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [89]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [44]
Ospemifene DMC4GEI Moderate Decreased metabolism of Voriconazole caused by Ospemifene mediated inhibition of CYP450 enzyme. Dyspareunia [GA12] [90]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Deutetrabenazine. Dystonic disorder [8A02] [91]
Ingrezza DMVPLNC Major Additive CNS depression effects by the combination of Voriconazole and Ingrezza. Dystonic disorder [8A02] [92]
Diazepam DM08E9O Moderate Decreased metabolism of Voriconazole caused by Diazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [93]
Zonisamide DM0DTF7 Moderate Decreased metabolism of Voriconazole caused by Zonisamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [45]
Primidone DM0WX6I Major Increased metabolism of Voriconazole caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [44]
Felbamate DM1V5ZS Moderate Increased metabolism of Voriconazole caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [54]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Voriconazole caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [54]
Ethosuximide DMDZ9LT Moderate Decreased metabolism of Voriconazole caused by Ethosuximide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [45]
Cenobamate DMGOVHA Moderate Decreased metabolism of Voriconazole caused by Cenobamate mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [94]
Tiagabine DMKSQG0 Moderate Decreased metabolism of Voriconazole caused by Tiagabine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [45]
Stiripentol DMMSDOY Moderate Decreased metabolism of Voriconazole caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [50]
Fosphenytoin DMOX3LB Major Increased metabolism of Voriconazole caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [95]
Brivaracetam DMSEPK8 Minor Decreased metabolism of Voriconazole caused by Brivaracetam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [50]
Clonazepam DMTO13J Moderate Decreased metabolism of Voriconazole caused by Clonazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [45]
Lacosamide DMVM6QR Moderate Decreased metabolism of Voriconazole caused by Lacosamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [45]
Rufinamide DMWE60C Moderate Increased metabolism of Voriconazole caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [50]
Phenobarbital DMXZOCG Major Increased metabolism of Voriconazole caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [44]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Voriconazole caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [54]
Cannabidiol DM0659E Minor Decreased metabolism of Voriconazole caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [50]
Nicardipine DMCDYW7 Moderate Decreased metabolism of Voriconazole caused by Nicardipine mediated inhibition of CYP450 enzyme. Essential hypertension [BA00] [58]
Mefenamic acid DMK7HFI Moderate Decreased metabolism of Voriconazole caused by Mefenamic acid mediated inhibition of CYP450 enzyme. Female pelvic pain [GA34] [45]
Bay 80-6946 DMLOS5R Major Decreased metabolism of Voriconazole caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [96]
Tazemetostat DMWP1BH Major Decreased metabolism of Voriconazole caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [97]
Solifenacin DMG592Q Major Decreased metabolism of Voriconazole caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [45]
Mirabegron DMS1GYT Minor Decreased metabolism of Voriconazole caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [98]
Tolterodine DMSHPW8 Moderate Decreased metabolism of Voriconazole caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [99]
Itraconazole DMCR1MV Moderate Decreased metabolism of Voriconazole caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [45]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Pentamidine. Fungal infection [1F29-1F2F] [44]
Miconazole DMPMYE8 Moderate Decreased metabolism of Voriconazole caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [45]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Voriconazole caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [45]
Cisapride DMY7PED Major Decreased metabolism of Voriconazole caused by Cisapride mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [100]
Ripretinib DM958QB Major Decreased metabolism of Voriconazole caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [45]
Avapritinib DMK2GZX Major Decreased metabolism of Voriconazole caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [50]
Colchicine DM2POTE Major Decreased metabolism of Voriconazole caused by Colchicine mediated inhibition of CYP450 enzyme. Gout [FA25] [101]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Voriconazole caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [54]
Ergotamine DMKR3C5 Major Decreased metabolism of Voriconazole caused by Ergotamine mediated inhibition of CYP450 enzyme. Headache [8A80-8A84] [102]
Eplerenone DMF0NQR Major Decreased metabolism of Voriconazole caused by Eplerenone mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [45]
Boceprevir DMBSHMF Moderate Decreased metabolism of Voriconazole caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [103]
Simeprevir DMLUA9D Major Decreased metabolism of Voriconazole caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [45]
Telaprevir DMMRV29 Moderate Decreased metabolism of Voriconazole caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [103]
Daclatasvir DMSFK9V Major Decreased metabolism of Voriconazole caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [50]
Rifampin DMA8J1G Major Increased metabolism of Voriconazole caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [44]
Rifapentine DMCHV4I Moderate Increased metabolism of Voriconazole caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [104]
Brentuximab vedotin DMWLC57 Moderate Decreased clearance of Voriconazole due to the transporter inhibition by Brentuximab vedotin. Hodgkin lymphoma [2B30] [54]
MK-1439 DM215WE Minor Decreased metabolism of Voriconazole caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [105]
Delavirdine DM3NF5G Moderate Decreased metabolism of Voriconazole caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [54]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Voriconazole caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [50]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [106]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Voriconazole caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [107]
Tipranavir DM8HJX6 Moderate Decreased metabolism of Voriconazole caused by Tipranavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [108]
Efavirenz DMC0GSJ Major Increased metabolism of Voriconazole caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [109]
Dolutegravir DMCZGRE Minor Decreased metabolism of Voriconazole caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [110]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Voriconazole and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [111]
Etravirine DMGV8QU Moderate Decreased metabolism of Voriconazole caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [112]
Rilpivirine DMJ0QOW Moderate Decreased metabolism of Voriconazole caused by Rilpivirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [113]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Voriconazole caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [50]
Atazanavir DMSYRBX Moderate Decreased metabolism of Voriconazole caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [50]
Maraviroc DMTL94F Major Decreased metabolism of Voriconazole caused by Maraviroc mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [114]
Simvastatin DM30SGU Major Decreased metabolism of Voriconazole caused by Simvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [115]
Fluvastatin DM4MDJY Moderate Decreased metabolism of Voriconazole caused by Fluvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [45]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Voriconazole caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [45]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Voriconazole and Mipomersen. Hyper-lipoproteinaemia [5C80] [116]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Voriconazole and Teriflunomide. Hyper-lipoproteinaemia [5C80] [44]
BMS-201038 DMQTAGO Major Decreased metabolism of Voriconazole caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [45]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Voriconazole caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [117]
Paricalcitol DMYBV3G Moderate Decreased metabolism of Voriconazole caused by Paricalcitol mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [50]
Aliskiren DM1BV7W Moderate Decreased clearance of Voriconazole due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [44]
Losartan DM72JXH Moderate Decreased metabolism of Voriconazole caused by Losartan mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [45]
Levamlodipine DM92S6N Moderate Decreased metabolism of Voriconazole caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [58]
Doxazosin DM9PLRH Moderate Decreased metabolism of Voriconazole caused by Doxazosin mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [44]
Verapamil DMA7PEW Moderate Decreased metabolism of Voriconazole caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [58]
Felodipine DMOSW35 Moderate Decreased metabolism of Voriconazole caused by Felodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [58]
Irbesartan DMTP1DC Moderate Decreased metabolism of Voriconazole caused by Irbesartan mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [45]
Tolvaptan DMIWFRL Major Decreased metabolism of Voriconazole caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [45]
Fludrocortisone DMUDIR8 Moderate Decreased metabolism of Voriconazole caused by Fludrocortisone mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [118]
Pirfenidone DM6VZFQ Moderate Decreased metabolism of Voriconazole caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [50]
Retapamulin DM9JXB7 Minor Decreased metabolism of Voriconazole caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [119]
Lesinurad DMUR64T Moderate Decreased metabolism of Voriconazole caused by Lesinurad mediated inhibition of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [120]
TP-434 DM5A31S Minor Decreased metabolism of Voriconazole caused by TP-434 mediated inhibition of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [121]
Suvorexant DM0E6S3 Major Decreased metabolism of Voriconazole caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [45]
Amobarbital DM0GQ8N Moderate Increased metabolism of Voriconazole caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [54]
Ramelteon DM7IW9J Moderate Decreased metabolism of Voriconazole caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [122]
Flurazepam DMAL4G0 Moderate Decreased metabolism of Voriconazole caused by Flurazepam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [45]
Triazolam DMETYK5 Major Decreased metabolism of Voriconazole caused by Triazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [123]
Zaleplon DMGFWSM Moderate Decreased metabolism of Voriconazole caused by Zaleplon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [45]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Voriconazole caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [124]
ITI-007 DMUQ1DO Major Decreased metabolism of Voriconazole caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [125]
Quazepam DMY4D87 Moderate Decreased metabolism of Voriconazole caused by Quazepam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [45]
Estazolam DMZGXUM Moderate Decreased metabolism of Voriconazole caused by Estazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [45]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Voriconazole and Polyethylene glycol. Irritable bowel syndrome [DD91] [50]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Voriconazole and Phenolphthalein. Irritable bowel syndrome [DD91] [44]
Alosetron DML2A03 Moderate Decreased metabolism of Voriconazole caused by Alosetron mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [126]
Eluxadoline DMYZ0P1 Moderate Decreased metabolism of Voriconazole caused by Eluxadoline mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [127]
Naloxegol DML0B41 Major Decreased metabolism of Voriconazole caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [45]
Testosterone DM7HUNW Moderate Decreased metabolism of Voriconazole caused by Testosterone mediated inhibition of CYP450 enzyme. Low bone mass disorder [FB83] [45]
Crizotinib DM4F29C Major Decreased metabolism of Voriconazole caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [45]
Brigatinib DM7W94S Major Decreased metabolism of Voriconazole caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [128]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Voriconazole and Porfimer Sodium. Lung cancer [2C25] [129]
Ceritinib DMB920Z Major Decreased metabolism of Voriconazole caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [45]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Voriconazole caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [130]
PF-06463922 DMKM7EW Major Decreased metabolism of Voriconazole caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [131]
Osimertinib DMRJLAT Major Decreased metabolism of Voriconazole caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [132]
Pralsetinib DMWU0I2 Major Decreased metabolism of Voriconazole caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [133]
Capmatinib DMYCXKL Major Decreased metabolism of Voriconazole caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [134]
Selpercatinib DMZR15V Major Decreased metabolism of Voriconazole caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [50]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Voriconazole and Lumefantrine. Malaria [1F40-1F45] [45]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Voriconazole and Halofantrine. Malaria [1F40-1F45] [135]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Voriconazole and Chloroquine. Malaria [1F40-1F45] [136]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Voriconazole and Hydroxychloroquine. Malaria [1F40-1F45] [136]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Primaquine. Malaria [1F40-1F45] [44]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [50]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Voriconazole and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [137]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Voriconazole and Idelalisib. Mature B-cell leukaemia [2A82] [138]
IPI-145 DMWA24P Major Decreased metabolism of Voriconazole caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [139]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Voriconazole and Arsenic trioxide. Mature B-cell lymphoma [2A85] [140]
Acalabrutinib DM7GCVW Major Decreased metabolism of Voriconazole caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [141]
Ibrutinib DMHZCPO Major Decreased metabolism of Voriconazole caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [45]
Ponatinib DMYGJQO Major Decreased metabolism of Voriconazole caused by Ponatinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [45]
Selumetinib DMC7W6R Major Decreased metabolism of Voriconazole caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [142]
LGX818 DMNQXV8 Major Decreased metabolism of Voriconazole caused by LGX818 mediated inhibition of CYP450 enzyme. Melanoma [2C30] [143]
Dabrafenib DMX6OE3 Moderate Decreased metabolism of Voriconazole caused by Dabrafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [45]
Estrone DM5T6US Moderate Decreased metabolism of Voriconazole caused by Estrone mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [72]
Dienestrol DMBSXI0 Moderate Decreased metabolism of Voriconazole caused by Dienestrol mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [89]
Ethinyl estradiol DMODJ40 Moderate Decreased metabolism of Voriconazole caused by Ethinyl estradiol mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [89]
Ubrogepant DM749I3 Major Decreased metabolism of Voriconazole caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [144]
Almogran DM7I64Z Moderate Decreased metabolism of Voriconazole caused by Almogran mediated inhibition of CYP450 enzyme. Migraine [8A80] [145]
Rimegepant DMHOAUG Moderate Decreased metabolism of Voriconazole caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [146]
Exjade DMHPRWG Moderate Increased metabolism of Voriconazole caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [54]
Flibanserin DM70DTN Major Decreased metabolism of Voriconazole caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [147]
Midazolam DMXOELT Major Decreased metabolism of Voriconazole caused by Midazolam mediated inhibition of CYP450 enzyme. Mood/affect symptom [MB24] [123]
Panobinostat DM58WKG Major Decreased metabolism of Voriconazole caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [148]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Voriconazole and Thalidomide. Multiple myeloma [2A83] [45]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Voriconazole and Siponimod. Multiple sclerosis [8A40] [45]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Voriconazole and Fingolimod. Multiple sclerosis [8A40] [44]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Voriconazole and Ozanimod. Multiple sclerosis [8A40] [149]
Deflazacort DMV0RNS Major Decreased metabolism of Voriconazole caused by Deflazacort mediated inhibition of CYP450 enzyme. Muscular dystrophy [8C70] [50]
Rifabutin DM1YBHK Major Increased metabolism of Voriconazole caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [54]
Romidepsin DMT5GNL Moderate Decreased metabolism of Voriconazole caused by Romidepsin mediated inhibition of CYP450 enzyme. Mycosis fungoides [2B01] [150]
Fedratinib DM4ZBK6 Major Decreased metabolism of Voriconazole caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [50]
Nilotinib DM7HXWT Major Decreased metabolism of Voriconazole caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [45]
Dasatinib DMJV2EK Major Decreased metabolism of Voriconazole caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [45]
Vorapaxar DMA16BR Major Decreased metabolism of Voriconazole caused by Vorapaxar mediated inhibition of CYP450 enzyme. Myocardial infarction [BA41-BA43] [45]
Modafinil DMYILBE Moderate Increased metabolism of Voriconazole caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [54]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Promethazine. Nausea/vomiting [MD90] [44]
Granisetron DMIUW25 Moderate Decreased metabolism of Voriconazole caused by Granisetron mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [45]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Voriconazole and Dolasetron. Nausea/vomiting [MD90] [44]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Ondansetron. Nausea/vomiting [MD90] [44]
E-2007 DMJDYNQ Minor Decreased metabolism of Voriconazole caused by E-2007 mediated inhibition of CYP450 enzyme. Neuropathy [8C0Z] [50]
Entrectinib DMMPTLH Major Decreased metabolism of Voriconazole caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [45]
Levomethadyl Acetate DM06HG5 Major Decreased metabolism of Voriconazole caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [151]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Lofexidine. Opioid use disorder [6C43] [44]
S-297995 DM26IH8 Moderate Decreased metabolism of Voriconazole caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [50]
Diclofenac DMPIHLS Moderate Decreased metabolism of Voriconazole caused by Diclofenac mediated inhibition of CYP450 enzyme. Osteoarthritis [FA00-FA05] [45]
Olaparib DM8QB1D Major Decreased metabolism of Voriconazole caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [45]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Rucaparib. Ovarian cancer [2C73] [44]
Dextropropoxyphene DM23HCX Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Dextropropoxyphene. Pain [MG30-MG3Z] [53]
Butorphanol DM5KYPJ Major Decreased metabolism of Voriconazole caused by Butorphanol mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [152]
Ibuprofen DM8VCBE Moderate Decreased metabolism of Voriconazole caused by Ibuprofen mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [45]
Buprenorphine DMPRI8G Moderate Decreased metabolism of Voriconazole caused by Buprenorphine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [153]
Hydrocodone DMQ2JO5 Major Decreased metabolism of Voriconazole caused by Hydrocodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [154]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Triclabendazole. Parasitic worm infestation [1F90] [44]
Istradefylline DM20VSK Major Decreased metabolism of Voriconazole caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [155]
Pimavanserin DMR7IVC Major Decreased metabolism of Voriconazole caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [156]
Bromocriptine DMVE3TK Moderate Decreased metabolism of Voriconazole caused by Bromocriptine mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [45]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Apomorphine. Parkinsonism [8A00] [44]
Abametapir DM2RX0I Moderate Decreased metabolism of Voriconazole caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [157]
Esomeprazole DM7BN0X Moderate Decreased metabolism of Voriconazole caused by Esomeprazole mediated inhibition of CYP450 enzyme. Peptic ulcer [DA61] [64]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Voriconazole and Macimorelin. Pituitary gland disorder [5A60-5A61] [158]
Lefamulin DME6G97 Major Decreased metabolism of Voriconazole caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [159]
Prednisone DM2HG4X Moderate Decreased metabolism of Voriconazole caused by Prednisone mediated inhibition of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [118]
Hydrocortisone DMGEMB7 Moderate Decreased metabolism of Voriconazole caused by Hydrocortisone mediated inhibition of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [118]
Ergonovine DM0VEC1 Major Decreased metabolism of Voriconazole caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [160]
Ritodrine DM4V6RL Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Ritodrine. Preterm labour/delivery [JB00] [61]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Degarelix. Prostate cancer [2C82] [50]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Voriconazole and ABIRATERONE. Prostate cancer [2C82] [50]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Nilutamide. Prostate cancer [2C82] [50]
Enzalutamide DMGL19D Moderate Increased metabolism of Voriconazole caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [54]
Darolutamide DMV7YFT Minor Decreased metabolism of Voriconazole caused by Darolutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [161]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Bicalutamide. Prostate cancer [2C82] [50]
Tamsulosin DM5QF9V Major Decreased metabolism of Voriconazole caused by Tamsulosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [45]
Silodosin DMJSBT6 Major Decreased metabolism of Voriconazole caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [45]
Dutasteride DMQ4TJK Moderate Decreased metabolism of Voriconazole caused by Dutasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [162]
Finasteride DMWV3TZ Moderate Decreased metabolism of Voriconazole caused by Finasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [45]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Levomepromazine. Psychotic disorder [6A20-6A25] [44]
Fluphenazine DMIT8LX Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Fluphenazine. Psychotic disorder [6A20-6A25] [44]
Ambrisentan DMD1QXW Minor Decreased metabolism of Voriconazole caused by Ambrisentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [163]
Riociguat DMXBLMP Moderate Decreased clearance of Voriconazole due to the transporter inhibition by Riociguat. Pulmonary hypertension [BB01] [45]
Everolimus DM8X2EH Major Decreased metabolism of Voriconazole caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [45]
Axitinib DMGVH6N Major Decreased metabolism of Voriconazole caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [45]
Temsirolimus DMS104F Major Increased metabolism of Voriconazole caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [45]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Voriconazole and Gatifloxacin. Respiratory infection [CA07-CA4Z] [164]
Ciclesonide DM2NA4K Moderate Decreased metabolism of Voriconazole caused by Ciclesonide mediated inhibition of CYP450 enzyme. Respiratory system disease [CB40-CB7Z] [118]
Meloxicam DM2AR7L Moderate Decreased metabolism of Voriconazole caused by Meloxicam mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [45]
Upadacitinib DM32B5U Major Decreased metabolism of Voriconazole caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [165]
Tofacitinib DMBS370 Major Decreased metabolism of Voriconazole caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [45]
Flurbiprofen DMGN4BY Moderate Decreased metabolism of Voriconazole caused by Flurbiprofen mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [45]
Dexamethasone DMMWZET Moderate Decreased metabolism of Voriconazole caused by Dexamethasone mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [166]
Nafcillin DMN9RPO Moderate Increased metabolism of Voriconazole caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [54]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Voriconazole and Leflunomide. Rheumatoid arthritis [FA20] [44]
Quetiapine DM1N62C Major Decreased metabolism of Voriconazole caused by Quetiapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [167]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Voriconazole and Mesoridazine. Schizophrenia [6A20] [44]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Voriconazole and Thioridazine. Schizophrenia [6A20] [44]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Voriconazole caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [168]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Voriconazole and Iloperidone. Schizophrenia [6A20] [44]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Paliperidone. Schizophrenia [6A20] [44]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Trifluoperazine. Schizophrenia [6A20] [44]
Risperidone DMN6DXL Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Risperidone. Schizophrenia [6A20] [44]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Voriconazole and Amisulpride. Schizophrenia [6A20] [45]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Asenapine. Schizophrenia [6A20] [44]
Pimozide DMW83TP Major Decreased metabolism of Voriconazole caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [45]
Fentanyl DM8WAHT Major Decreased metabolism of Voriconazole caused by Fentanyl mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [45]
Sufentanil DMU7YEL Moderate Decreased metabolism of Voriconazole caused by Sufentanil mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [169]
Avanafil DM75CXN Major Decreased metabolism of Voriconazole caused by Avanafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [45]
Tadalafil DMJZHT1 Moderate Decreased metabolism of Voriconazole caused by Tadalafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [45]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Vardenafil. Sexual dysfunction [HA00-HA01] [44]
Voxelotor DMCS6M5 Major Decreased metabolism of Voriconazole caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [170]
LDE225 DMM9F25 Major Decreased metabolism of Voriconazole caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [171]
Larotrectinib DM26CQR Major Decreased metabolism of Voriconazole caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [45]
Docetaxel DMDI269 Major Decreased clearance of Voriconazole due to the transporter inhibition by Docetaxel. Solid tumour/cancer [2A00-2F9Z] [172]
Trabectedin DMG3Y89 Major Decreased metabolism of Voriconazole caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [45]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Voriconazole and LEE011. Solid tumour/cancer [2A00-2F9Z] [173]
Etoposide DMNH3PG Moderate Decreased metabolism of Voriconazole caused by Etoposide mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [45]
Prednisolone DMQ8FR2 Moderate Decreased metabolism of Voriconazole caused by Prednisolone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [118]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Voriconazole and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [44]
Norethindrone DMTY169 Moderate Decreased metabolism of Voriconazole caused by Norethindrone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [89]
Taxol DMUOT9V Moderate Decreased metabolism of Voriconazole caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [174]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [53]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Pitolisant. Somnolence [MG42] [44]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [44]
Ivermectin DMDBX5F Moderate Decreased metabolism of Voriconazole caused by Ivermectin mediated inhibition of CYP450 enzyme. Strongyloidiasis [1F6B] [50]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Voriconazole and Naltrexone. Substance abuse [6C40] [175]
Warfarin DMJYCVW Major Decreased metabolism of Voriconazole caused by Warfarin mediated inhibition of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [54]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Voriconazole and Adenosine. Supraventricular tachyarrhythmia [BC81] [44]
Pomalidomide DMTGBAX Moderate Decreased metabolism of Voriconazole caused by Pomalidomide mediated inhibition of CYP450 enzyme. Systemic sclerosis [4A42] [45]
Fostamatinib DM6AUHV Major Decreased metabolism of Voriconazole caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [176]
As-1670542 DMV05SW Moderate Decreased metabolism of Voriconazole caused by As-1670542 mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [50]
Apixaban DM89JLN Major Decreased clearance of Voriconazole due to the transporter inhibition by Apixaban. Thrombosis [DB61-GB90] [45]
Brilinta DMBR01X Major Decreased metabolism of Voriconazole caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [45]
Clopidogrel DMOL54H Moderate Decreased metabolism of Voriconazole caused by Clopidogrel mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [177]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Lenvatinib. Thyroid cancer [2D10] [44]
Cabozantinib DMIYDT4 Major Decreased metabolism of Voriconazole caused by Cabozantinib mediated inhibition of CYP450 enzyme. Thyroid cancer [2D10] [45]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Voriconazole and Papaverine. Tonus and reflex abnormality [MB47] [178]
Tizanidine DMR2IQ4 Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Tizanidine. Tonus and reflex abnormality [MB47] [44]
Sirolimus DMGW1ID Major Decreased metabolism of Voriconazole caused by Sirolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [44]
Tacrolimus DMZ7XNQ Major Decreased metabolism of Voriconazole caused by Tacrolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [179]
Tolbutamide DM02AWV Major Decreased metabolism of Voriconazole caused by Tolbutamide mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [49]
Saxagliptin DMGXENV Moderate Decreased metabolism of Voriconazole caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [50]
Chlorpropamide DMPHZQE Major Decreased metabolism of Voriconazole caused by Chlorpropamide mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [49]
Elagolix DMB2C0E Major Decreased metabolism of Voriconazole caused by Elagolix mediated inhibition of CYP450 enzyme. Uterine fibroid [2E86] [180]
Fexofenadine DM17ONX Minor Decreased clearance of Voriconazole due to the transporter inhibition by Fexofenadine. Vasomotor/allergic rhinitis [CA08] [181]
Astemizole DM2HN6Q Major Decreased metabolism of Voriconazole caused by Astemizole mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [182]
Triamcinolone DM98IXF Major Decreased metabolism of Voriconazole caused by Triamcinolone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [118]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [53]
Fluticasone DMGCSVF Major Decreased metabolism of Voriconazole caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [183]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Voriconazole and Procainamide. Ventricular tachyarrhythmia [BC71] [44]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Propafenone. Ventricular tachyarrhythmia [BC71] [44]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Voriconazole and Flecainide. Ventricular tachyarrhythmia [BC71] [44]
Amiodarone DMUTEX3 Major Decreased metabolism of Voriconazole caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [184]
⏷ Show the Full List of 367 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Carmellose sodium E00625 Not Available Disintegrant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 13 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Voriconazole 200 mg tablet 200 mg Oral Tablet Oral
Voriconazole 50 mg tablet 50 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole. J Microbiol Immunol Infect. 2009 Apr;42(2):148-53.
2 VFEND? FDA Label
3 BDDCS applied to over 900 drugs
4 Shi C, Xiao Y, Mao Y, Wu J, Lin N: Voriconazole: A Review of Population Pharmacokinetic Analyses. Clin Pharmacokinet. 2019 Jun;58(6):687-703. doi: 10.1007/s40262-019-00735-7.
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltran E, Vigneri S, Edvinsson L, Maassen Van Den Brink A: Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain. 2017 Sep 25;18(1):96. doi: 10.1186/s10194-017-0807-1.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9 Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol. 2007 Jun 15;73(12):2020-6.
10 Effect of voriconazole on the pharmacokinetics of diclofenac. Fundam Clin Pharmacol. 2007 Dec;21(6):651-6.
11 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
12 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
21 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
22 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
23 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
24 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
25 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
26 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
27 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
28 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
29 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
30 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
31 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
32 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
33 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
34 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
35 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
36 Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
37 A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity. Mycoses. 2006;49 Suppl 1:2-6.
38 Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302.
39 Antifungal agents: mechanisms of action. Trends Microbiol. 2003 Jun;11(6):272-9.
40 Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9.
41 Investigation of the role of cytochrome P450 2B4 active site residues in substrate metabolism based on crystal structures of the ligand-bound enzyme. Arch Biochem Biophys. 2006 Nov 1;455(1):61-7.
42 Biological spectra analysis: Linking biological activity profiles to molecular structure. Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):261-6.
43 Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homolo... Antimicrob Agents Chemother. 2008 Oct;52(10):3597-603.
44 Canadian Pharmacists Association.
45 Cerner Multum, Inc. "Australian Product Information.".
46 Product Information. Cleocin (clindamycin). Pharmacia and Upjohn, Kalamazoo, MI.
47 Adamson PC "Pharmacokinetics of all-trans-retinoic acid: clinical implications in acute promyelocytic leukemia." Semin Hematol 31 (1994): 14-7. [PMID: 7831580]
48 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
49 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
50 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
51 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
52 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
53 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
54 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
55 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
56 Product Information. Reminyl (galantamine) Janssen Pharmaceuticals, Titusville, NJ.
57 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
58 Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086]
59 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
60 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
61 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
62 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
63 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
64 Eiden C, Peyriere H, Tichit R, et al. "Inherited long QT syndrome revealed by antifungals drug-drug interaction." J Clin Pharm Ther 32 (2007): 321-4. [PMID: 17489884]
65 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
66 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
67 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
68 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
69 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
70 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
71 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
72 Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9. [PMID: 2547410]
73 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
74 Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
75 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
76 Akram K, Rao S, Parker M "A lesson for everyone in drug-drug interactions." Int J Cardiol 118 (2007): e19-20. [PMID: 17368833]
77 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
78 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
79 Product Information. Fetzima (levomilnacipran). Forest Pharmaceuticals, St. Louis, MO.
80 Bartkowski RR, Goldberg ME, Larijani GE, Boerner T "Inhibition of alfentanil metabolism by erythromycin." Clin Pharmacol Ther 46 (1989): 99-102. [PMID: 2501060]
81 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
82 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
83 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
84 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
85 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
86 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
87 Dattilo PB, Nordin C "Prolonged QT associated with an overdose of trazodone." J Clin Psychiatry 68 (2007): 1309-10. [PMID: 17854263]
88 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
89 Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33. [PMID: 2330488]
90 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
91 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
92 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
93 Ahonen J, Olkkola KT, Neuvonen PJ "The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam." Fundam Clin Pharmacol 10 (1996): 314-8. [PMID: 8836707]
94 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
95 Alffenaar JW, van der Elst KC, Uges DR, Kosterink JG, Daenen SM "Phenytoin-induced reduction of voriconazole serum concentration is not compensated by doubling the dosage." Br J Clin Pharmacol 68 (2009): 462-3. [PMID: 19740405]
96 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
97 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
98 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
99 Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027]
100 Bedford TA, Rowbotham DJ "Cisapride: drug interactions of clinical significance." Drug Saf 15 (1996): 167-75. [PMID: 8879971]
101 Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
102 Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
103 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
104 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
105 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
106 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
107 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
108 Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
109 Carbonara S, Regazzi M, Ciraci E, et al. "Long-term Efficacy and safety of TDM-assisted combination of voriconazole plus efavirenz in an AIDS patient with cryptococcosis and liver cirrhosis." Ann Pharmacother 43 (2009): 978-84. [PMID: 19383934]
110 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
111 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
112 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
113 Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
114 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
115 Ayanian JZ, Fuchs CS, Stone RM "Lovastatin and rhabdomyolysis." Ann Intern Med 109 (1988): 682-3. [PMID: 3421582]
116 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
117 Product Information. Sensipar (cinacalcet). Amgen USA, Thousand Oaks, CA.
118 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
119 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
120 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
121 Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
122 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
123 Ahonen J, Olkkola KT, Neuvonen PJ "Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers." Br J Clin Pharmacol 40 (1995): 270-2. [PMID: 8527290]
124 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
125 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
126 Product Information. Lotronex (alosetron). Glaxo Wellcome, Research Triangle Park, NC.
127 Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
128 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
129 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
130 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
131 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
132 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
133 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
134 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
135 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
136 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
137 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
138 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
139 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
140 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
141 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
142 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
143 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
144 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
145 Product Information. Axert (almotriptan) Pharmacia and Upjohn, Kalamazoo, MI.
146 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
147 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
148 Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
149 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
150 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
151 Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
152 Product Information. Butorphanol Tartrate (butorphanol). Apotex Corporation, Weston, FL.
153 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
154 Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA "CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes." Br J Clin Pharmacol 57 (2004): 287-97. [PMID: 14998425]
155 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
156 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
157 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
158 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
159 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
160 Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D "Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir." Postgrad Med J 75 (1999): 546-7. [PMID: 10616689]
161 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
162 Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
163 Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
164 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
165 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
166 Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease." Clin Pharmacokinet 43 (2004): 803-21. [PMID: 15355126]
167 DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
168 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
169 Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5. [PMID: 8439020]
170 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
171 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
172 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
173 Product Information. Kisqali (ribociclib). Novartis Pharmaceuticals, East Hanover, NJ.
174 Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
175 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
176 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
177 Collet JP, Hulot JS, Pena A, et al. "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study." Lancet 373 (2009): 309-17. [PMID: 19108880]
178 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
179 Albengres E, Le Louet H, Tillement JP "Systemic antifungal agents. Drug interactions of clinical significance." Drug Saf 18 (1998): 83-97. [PMID: 9512916]
180 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
181 Product Information. Allegra (fexofenadine). Hoechst Marion-Roussel Inc, Kansas City, MO.
182 Ament PW, Paterson A "Drug interactions with the nonsedating antihistamines." Am Fam Physician 56 (1997): 223. [PMID: 9225677]
183 Arrington-Sanders R, Hutton N, Siberry GK "Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents." Pediatr Infect Dis J 25 (2006): 1044-1048. [PMID: 17072128]
184 Fabre G, Julian B, Saint-Aubert B, Joyeux H, Berger Y "Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions." Drug Metab Dispos 21 (1993): 978-85. [PMID: 7905403]